Herschorn, S., Nazir, J., Ramos, B., & Hakimi, Z. (2017). Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada. Canadian Urological Association Journal, 11(3-4), 123–30. https://doi.org/10.5489/cuaj.4114